Long Non-Coding RNAs Modulate Sjögren’s Syndrome Associated Gene Expression and Are Involved in the Pathogenesis of the Disease

Marzia Dolcino 1, Elisa Tinazzi 1, Claudio Vitali 2, Nicoletta Del Papa 3, Antonio Puccetti 4,† and Claudio Lunardi 1,*,†,‡

1 Department of Medicine, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy
2 Sections of Rheumatology, Villa S. Giuseppe, Como and Casa di Cura di Lecco, 23900 Lecco, Italy
3 U.O.C. Day Hospital Reumatologia, ASST G. Pini-CTO, 20122 Milan, Italy
4 Department of Experimental Medicine, Section of Histology, University of Genova, Via G.B. Marsano 10, 16132 Genova, Italy
* Correspondence: claudio.lunardi@univr.it
† These authors contributed equally to this work.

Received: 31 July 2019; Accepted: 27 August 2019; Published: 1 September 2019

Abstract: Primary Sjögren’s syndrome (pSjS) is a chronic systemic autoimmune disorder, primarily affecting exocrine glands; its pathogenesis is still unclear. Long non-coding RNAs (lncRNAs) are thought to play a role in the pathogenesis of autoimmune diseases and a comprehensive analysis of lncRNAs expression in pSjS is still lacking. To this aim, the expression of more than 540,000 human transcripts, including those ascribed to more than 50,000 lncRNAs is profiled at the same time, in a cohort of 16 peripheral blood mononuclear cells PBMCs samples (eight pSjS and eight healthy subjects). A complex network analysis is carried out on the global set of molecular interactions among modulated genes and lncRNAs, leading to the identification of reliable lncRNA-miRNA-gene functional interactions. Taking this approach, a few lncRNAs are identified as targeting highly connected genes in the pSjS transcriptome, since they have a major impact on gene modulation in the disease. Such genes are involved in biological processes and molecular pathways crucial in the pathogenesis of pSjS, including immune response, B cell development and function, inflammation, apoptosis, type I and gamma interferon, epithelial cell adhesion and polarization. The identification of deregulated lncRNAs that modulate genes involved in the typical features of the disease provides insight in disease pathogenesis and opens avenues for the design of novel therapeutic strategies.

Keywords: primary Sjögren’s syndrome; long non-coding RNA; signaling pathway; protein–protein (PPI) network; gene module

1. Introduction

Sjögren’s syndrome (SjS) is a chronic systemic autoimmune disease of still unknown origin, that may be present either alone (defined as primary SjS: pSjS) or associated with other autoimmune diseases (defined as secondary SjS). The prevalence of pSjS in the general population is between 0.01 and 0.1% with a higher prevalence of the disease in women [1,2]. The clinical symptoms of pSjS include exocrinopathy, resulting in dry eyes and mouth and extraglandular systemic manifestations such as arthralgias, fatigue, vasculitis, pulmonary fibrosis and pulmonary hypertension, interstitial nephritis and central and peripheral involvement of the nervous system [3].

Although little is known on the pathogenesis of the disease, several factors have been shown to contribute to its onset, such as genetic background, environmental factors including viral infections [4] and epigenetic mechanisms, such as microRNAs (miRNAs).
Our attention is focused on the epigenetic mechanisms that may be involved in pSjS pathogenesis, through the analysis of the modulation of long non-coding RNAs (lncRNAs) expression in pSjS patients. The identification of lncRNAs modulated in the disease and an integrated analysis of lncRNAs, miRNAs and gene expression profiles in patients affected by pSjS are reported here as an historical first, to the best of the authors’ knowledge. Interestingly, the identified lncRNAs are able to modulate pathogenetically relevant molecular pathways of the disease.

2. Materials and Methods

2.1. Patients

Eight female patients (mean age 52 ± 15 years old) affected by pSjS, attending the Unit of Autoimmune Diseases at the University Hospital of Verona, Northern Italy, and 8 sex and age matched healthy controls were enrolled. Both patients and controls were subjects of Caucasian origin from Northern Italy. All patients enrolled in this study were diagnosed according to the American College of Rheumatology (ACR)-European League against Rheumatism (EULAR) criteria [5]. They underwent labial salivary gland biopsy and disease activity was evaluated at the moment of enrollment in the study.

A written informed consent was obtained from all the participants of the study and the study protocol was approved by the Ethical Committee of the Azienda Ospedaliera Universitaria Integrita di Verona (identification code 1538, version 3, date of approval 12 March 2012). All the investigations have been performed according to the principles contained in the Helsinki declaration.

2.2. Microarray Analysis

Blood sample collection was carried out using BD Vacutainer K2EDTA tubes (Becton Dickinson, Franklin Lakes, NJ, USA) and 21-gauge needles.

PBMCs isolation was performed by Ficoll–HyPaque (Pharmacia Biotech, Piscataway, NJ, USA) gradient centrifugation. Patients and controls had similar PBMCs distribution. Total RNA was extracted from PBMCs (10⁷ cells) using an miRNeasy mini kit (Qiagen GmbH, Hilden, Germany). cRNA preparation, samples hybridization and scanning were performed following the Affymetrix (Affymetrix, Santa Clara, CA, USA) provided protocols using a Cogentech Affymetrix microarray unit (Campus IFOM IEO, Milan, Italy). All samples were hybridized on a Human Clarion D (Thermo Fisher Scientific, Waltham, MA, USA) gene chip. Signal intensities were analysed with the Transcriptome Analysis Console (TAC) 4.0 software (Applied Biosystem, Foster City, CA, USA by Thermo Fisher Scientific, Waltham, MA, USA).

Using the Human Clarion D arrays, more than 540,000 human transcripts were interrogated, starting from as little as 100 pg of total RNA. Signal intensity was background-adjusted, normalized, and log-transformed using the Signal Space Transformation (SST)-Robust Multi-Array Average algorithm (RMA). Differentially expressed genes that showed an expression level at least 1.5 fold different in the test sample versus control sample at a significant level (p ≤ 0.01) were chosen for final consideration. p-values were calculated applying the unpaired t-test and Bonferroni multiple testing correction.

Target annotations of long non-coding RNAs were retrieved using starBase v2.0 (http://starbase.sysu.edu.cn/) where lncRNAs interactions, experimentally validated by high-throughput experimental technologies, are registered [6].

The list of gene targets of microRNAs (miRNAs) that were targeted by lncRNAs were inferred interrogating the FunRich database (www.funrich.org/) [7].

2.3. Protein–Protein Interaction (PPI) Network Construction and Network Clustering

The PPI network was constructed upon the experimentally validated protein–protein interactions using STRING (Search Tool for the Retrieval of Interacting Genes) version 10.5 (http://string-db.org/) [8].
Network topological analysis was performed using the Cytoscape software (version 3.7, [www.cytoscape.org] [9]). High-flow areas (highly connected regions) of the network (modules) were detected using the MCODE plugin of Cytoscape (k-core = 4 and node score cutoff = 0.2).

2.4. Gene Functional Classification and Enrichment Analysis

Genes were classified functionally into Biological Processes (BPs) according to the Gene Ontology (GO) project annotations ([www.geneontology.org](http://www.geneontology.org)) by the Panther expression analysis tools ([http://pantherdb.org/](http://pantherdb.org/)) [10].

Pathway classification and enrichment (hypergeometric p-value ≤ 0.05) analysis were achieved with FunRich.

2.5. Real Time PCR of lncRNAs

Five hundred ng of total RNA was treated with 1 unit of DNase I Amplification Grade (Invitrogen; Carlsbad, CA, USA). First-strand cDNA was generated using the SuperScript IV First-Strand Synthesis System (Invitrogen; Carlsbad, CA, USA) with random hexamers, according to the manufacturer’s protocol. Real time PCR was performed in triplicate with PowerUp™ Sybr® Green reagent (Applied Biosystems; Foster City, CA, USA) in a QuantStudio 6 Flex system (Applied Biosystems; Foster City, CA, USA). Transcripts of relative expression levels were obtained after normalization against the geometric mean of the housekeeping genes Glyceraldehyde 3-phosphate dehydrogenase GAPDH and beta-actin (ACTB) expression. The \( \Delta \Delta C_t \) method of relative quantification was used for comparing relative fold expression differences. Results are expressed as fold changes with respect to healthy subjects.

2.6. Real Time PCR of Genes Modulated in pSjS Patients

First-strand cDNA was obtained using the SuperScript III First-Strand Synthesis System for RT-PCR Kit (Invitrogen), with random hexamers, following the manufacturer’s protocol. PCR was performed in a total volume of 25 µL containing 1× Taqman Universal PCR Master mix, no AmpErase UNG and 2.5 µL of cDNA; pre-designed, gene-specific primers and probe sets for each gene were obtained from Assay-on-Demande Gene Expression Products service (Applied Biosystems). Real-Time PCR reactions were carried out in a two-tube system and in singleplex. The Real-Time amplifications encompassed 10 min at 95 °C (AmpliTaq Gold activation), followed by 40 cycles at 95 °C for 15 s and at 60 °C for one minute. Thermocycling and signal detection were performed with a 7500 Sequence Detector (Applied Biosystems). Signals were detected following the manufacturer’s instructions. This methodology allowed the identification of the cycling point where the PCR product was detectable by means of fluorescence emission (Threshold cycle or Ct value). The Ct value correlated to the quantity of target mRNA. Relative expression levels were calculated for each sample after normalization against the housekeeping genes GAPDH, beta-actin and 18 s ribosomal RNA (rRNA) using the \( \Delta \Delta C_t \) method for comparing relative fold expression differences. Ct values for each reaction were determined using TaqMan SDS analysis software. Each amount of RNA tested had triplicate Ct values averaged. Since Ct values varied linearly with the logarithm of the amount of RNA, this average represented a geometric mean.

2.7. Real Time PCR of microRNAs

miRNAs expression was evaluated by TaqMan® Advanced miRNA assays chemistry (Applied Biosystems, Foster City, CA, USA). Briefly, 10 ng of total RNA was reverse transcribed and pre-amplified with a TaqMan® Advanced miRNA cDNA synthesis kit according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA). Pre-amplified cDNA was diluted 1/10 in nuclease-free water and 5 µL of diluted cDNA for each replicate was loaded in PCR. Twenty µL PCR reactions were composed by 2× Fast Advanced Master Mix and TaqMan® Advanced miRNA assays for miR-30e-5p, miR-32-5p, miR-155-5p, miR-195-5p, miR-378a-3p and miR-30b-5p. The mean of Ct for hsa-miR-16-5p
and hsa-miR-26a-5p expression was used to normalize miRNA expression. Real time PCR was carried out in triplicate on a QuantStudio 6 Flex instrument (Applied Biosystems, Foster City, CA, USA). Expression values were reported as fold change with respect to healthy controls by $\Delta\Delta^{Ct}$ method employing QuantStudio Real-Time PCR system software v. 1.3.

3. Results

3.1. Patients Characteristics

All the patients enrolled in the study had antinuclear antibodies >1:640, nuclear dots or homogeneous patterns, and were positive for anti-ENA antibodies SSA/Ro; four of them also were positive for anti-SSB antibodies. Labial salivary gland histopathology showed a focal lymphocytic sialadenitis with a focus score >1 [11]. The median Eular Sjogren’s syndrome disease activity index (ESSDAI) score was 6. The median Eular Sjogren’s syndrome Patient Reported Index (ESSPRI) score was 7 [12]. Three patients presented germinal centre-like structures in their labial salivary gland biopsy and one patient developed a B cell lymphoma soon after enrollment in the study.

3.2. High-Throughput Gene and Long Non-Coding RNA Expression Profiling in Peripheral Blood Mononuclear Cells of Patients with pSjS

Intending to identify lncRNAs potentially involved in pSjS pathogenesis, the expression of more than 540,000 human transcripts, including those ascribed to more than 50,000 lncRNAs, was profiled at the same time, in a cohort of 16 PBMCs samples (8 pSjS and 8 healthy subjects). Transcriptional profiles of pSjS patients and healthy subjects were compared and, after a robust filtering procedure (Bonferroni-corrected $p$-value $\leq 0.01$ and fold change $\geq 1.5$), 2503 coding-genes were modulated significantly (Table S1).

The functional classification by Gene Ontology (http://www.geneontology.org/) of the 2503 differentially expressed genes (DEGs) revealed that they were involved in meaningful biological processes (BPs) known to play a role in the disease, including apoptosis, cell adhesion, immune response, type I Interferon signaling, Interferon-gamma signaling, extracellular matrix (ECM) organization and morphogenesis of a branching epithelium. A selection of genes that play a role in the above mentioned BPs is shown in Table 1.
Table 1. Selection of significant differentially expressed genes in pSjS patients versus healthy subjects, grouped according to the biological processes to which they are ascribed.

| Gene Symbol | Description                                      | Fold Change | p-Value | mRNA Accession |
|-------------|--------------------------------------------------|-------------|---------|----------------|
| **Apoptosis** |                                                  |             |         |                |
| CCAR2 | cell cycle and apoptosis regulator 2             | 1.83        | 0.002   | NM_021174      |
| CASP10 | caspase 10                                       | 2.26        | 0.004   | NM_001206524   |
| BCL2L13 | BCL2-like 13 (apoptosis facilitator)             | 2.49        | <0.001  | NM_001270726   |
| BCL2L12 | BCL2-like 12 (proline rich)                     | 2.44        | 0.002   | NM_001040668   |
| PYCARD | PYD and CARD domain containing                   | 2.52        | 0.004   | NM_013258      |
| DAPK3 | death-associated protein kinase 3                | 2.09        | <0.001  | NM_001348      |
| PDCD6 | programmed cell death 6                          | 2.93        | <0.001  | NM_001267556   |
| CASP9 | caspase 9                                        | 2.01        | <0.001  | NM_001229      |
| DEDD2 | death effector domain containing 2               | 3.82        | <0.001  | NM_001270614   |
| BMF | Bcl2 modifying factor                            | 1.88        | 0.003   | NM_001003940   |
| PDCD7 | programmed cell death 7                         | 1.98        | 0.001   | NM_005707      |
| FADD | Fas (TNFRSF6)-associated via death domain        | 2.06        | <0.001  | NM_003824      |
| ANP32B | acidic nuclear phosphoprotein 32 family member B | 2.34        | <0.001  | NM_006401      |
| BR3 | brain protein 13                                 | 1.87        | 0.003   | NM_001159491   |
| CLPTM1L | CLPTM1-like                                     | 2.8         | <0.001  | NM_0030782     |
| ING2 | inhibitor of growth family member 2             | 1.97        | <0.001  | NM_001291959   |
| BFAR | bifunctional apoptosis regulator                 | 1.98        | 0.003   | NM_016561      |
| DAP | death-associated protein                         | 2.42        | 0.004   | NM_001291963   |
| SORT1 | sortilin 1                                       | 2.51        | 0.008   | NM_001205228   |
| RRAGA | Ras-related GTP binding A                       | 1.76        | 0.001   | NM_006570      |
| **Cell adhesion** |                                              |             |         |                |
| LIN7C | lin-7 homolog C (C. elegans)                    | −1.76       | 0.001   | NM_018362      |
| ITGB3BP | integrin beta 3 binding protein (beta3-endonexin) | −2.87       | 0.001   | NM_001206739   |
| PRKCE | protein kinase C, epsilon                        | −1.62       | 0.005   | NM_005400      |
| FER | fer (fps/fes related) tyrosine kinase            | −2.3        | 0.001   | NM_001308028   |
| ADAM8 | ADAM metallopeptidase domain 8                  | 3.13        | <0.001  | NM_001109      |
| ADAM15 | ADAM metallopeptidase domain 15                | 3.59        | <0.001  | NM_001261464   |
| CLDN5 | claudin 5                                       | 1.69        | 0.007   | NM_001130861   |
| EMP2 | epithelial membrane protein 2                   | 1.71        | 0.005   | NM_001424      |
| ICAM3 | intercellular adhesion molecule 3               | 2.86        | <0.001  | NM_002162      |
| HN1 | hematological and neurological expressed 1       | 2.71        | <0.001  | NM_001002032   |
| Gene Symbol | Description | Fold Change | p-Value | mRNA Accession |
|-------------|-------------|-------------|---------|----------------|
| ITGA5       | integrin alpha 5 | 2.22 | <0.001 | NM_002205 |
| MISP        | mitotic spindle positioning | 1.86 | 0.003 | NM_173481 |
| PTPRJ       | protein tyrosine phosphatase, receptor type, J | 1.71 | 0.006 | NM_001098503 |
| RHOC        | ras homolog family member C | 2.5 | 0.004 | NM_001042678 |
| ZEB1        | zinc finger E-box binding homeobox 1 | -4.18 | <0.001 | NM_001128128 |
| ZFYVE21     | zinc finger, FYVE domain containing 21 | 3.07 | 0.001 | NM_001198953 |

**Immune response**

| Gene Symbol | Description | Fold Change | p-Value | mRNA Accession |
|-------------|-------------|-------------|---------|----------------|
| LAMTOR2     | late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 | 3.08 | 0.002 | NM_001145264 |
| IL6R        | interleukin 6 receptor | 1.79 | 0.001 | NM_000565 |
| IGKV3D-7    | immunoglobulin kappa variable 3D-7 | 4.17 | 0.004 | OTTHUMT00000476805 |
| IGLV3-19    | immunoglobulin lambda variable 3-19 | 6.58 | 0.002 | OTTHUMT00000321830 |
| HLA-G       | major histocompatibility complex, class I, G | 2.96 | <0.001 | NM_002127 |
| NCF1        | neutrophil cytosolic factor 1 | 2.17 | 0.003 | NM_000265 |
| CD68        | CD68 molecule | 2.18 | 0.002 | NM_001040059 |
| DEF6        | DEF6 guanine nucleotide exchange factor | 1.58 | 0.003 | NM_022047 |
| LILRA6      | leukocyte immunoglobulin-like receptor, subfamily A, member 6 | 2.37 | 0.004 | NM_024318 |
| TRBV24-1    | T cell receptor beta variable 24-1 | 3.57 | 0.001 | OTTHUMT00000352499 |
| IL5RA       | interleukin 5 receptor, alpha | 2.14 | <0.001 | NM_000564 |
| CD6         | CD6 molecule | 3.71 | <0.001 | NM_001254750 |
| CD7         | CD7 molecule | 1.93 | <0.001 | NM_006137 |
| BTK         | Bruton agammaglobulinemia tyrosine kinase | 1.79 | 0.006 | NM_000061 |
| BAX         | BCL2-associated X protein | 3.14 | <0.001 | NM_001291428 |
| BAK1        | BCL2-antagonist/killer 1 | 2.46 | 0.005 | NM_001188 |
| GATA3       | GATA binding protein 3 | 1.74 | 0.008 | NM_001002295 |
| TAP1        | antigen peptide transporter 1 | 2.58 | <0.001 | NM_001292022 |
| TAP2        | antigen peptide transporter 2 | 2.23 | 0.002 | NM_018833 |
| IL17RA      | interleukin 17 receptor A | 2.52 | 0.001 | NM_001289905 |
| IL23A       | interleukin 23, alpha subunit p19 | -2.9 | 0.009 | NM_016584 |
| IL4R        | interleukin 4 receptor | 2.37 | <0.001 | NM_000418 |
| CD33        | CD33 molecule | 3.39 | 0.002 | NM_001082618 |
| IL2RA       | interleukin 2 receptor, alpha | 1.89 | 0.006 | NM_000417 |
| LAT         | linker for activation of T-cells | 3.25 | <0.001 | NM_001014987 |
| C1RL        | complement component 1, r subcomponent-like | 1.52 | 0.010 | NM_001297640 |
| FCGRI1A     | Fc fragment of IgG, high affinity Ia, receptor (CD64) | 3.2 | <0.001 | NM_000566 |
| Gene Symbol | Description | Fold Change | p-Value | mRNA Accession |
|-------------|-------------|-------------|---------|----------------|
| CD81        | CD81 molecule | 2.04        | 0.008   | NM_001297649   |
| KLHL20      | kelch-like family member 20 | −1.94 | 0.004 | NM_014458 |
| KLHL6       | kelch-like family member 6 | 2.18 | 0.005 | NM_130446 |
| ORAI1       | ORAI calcium release-activated calcium modulator 1 | 2.97 | <0.001 | NM_032790 |
| CBX8        | chromobox homolog 8 | 1.62 | 0.008 | NM_020649 |
| ENO1        | enolase 1, (alpha) | 1.91 | 0.004 | NM_001201483 |
| GNAI2       | guanine nucleotide binding protein, alpha inhibiting activity polypeptide 2 | 1.67 | 0.007 | NM_001166425 |
| SPI1        | Spi-1 proto-oncogene | 1.73 | 0.007 | NM_001080547 |
| TRAF3       | TNF receptor-associated factor 3 | −1.63 | 0.009 | NM_001199427 |
| HNRNPL      | heterogeneous nuclear ribonucleoprotein L | 2.16 | 0.001 | NM_001055335 |
| FOSL1       | FOS-like antigen 1 | −2.14 | 0.008 | NM_001300844 |
| IRF5        | interferon regulatory factor 5 | 2.24 | 0.003 | NM_00108627 |
| IRF7        | interferon regulatory factor 7 | 3.14 | 0.002 | NM_001572 |
| IRF9        | interferon regulatory factor 9 | 2.68 | <0.001 | NM_006084 |
| MYD88       | myeloid differentiation primary response 88 | 1.86 | 0.005 | NM_001172666 |
| HLA-H       | major histocompatibility complex, class I, H (pseudogene) | 2.18 | 0.004 | NR_001434 |
| OAS1        | 2-5-oligoadenylate synthetase 1 | 3.58 | 0.002 | NM_01032409 |
| IFI35       | interferon-induced protein 35 | 1.78 | 0.007 | NM_005533 |
| IFITM3      | interferon induced transmembrane protein 3 | 2.54 | 0.006 | NM_021034 |
| IFNA10      | interferon, alpha 10 | 1.99 | 0.002 | NM_002171 |
| ADAR        | adenosine deaminase, RNA-specific | 3.15 | 0.005 | NM_001025107 |
| OAS3        | 2-5-oligoadenylate synthetase 3 | 4.27 | 0.008 | NM_006187 |
| STAT1       | signal transducer and activator of transcription 1 | 1.75 | 0.008 | NM_007315 |
| KLHL20      | kelch-like family member 20 | −1.94 | 0.004 | NM_014458 |

**Type I interferon signaling**

| Gene Symbol | Description | Fold Change | p-Value | mRNA Accession |
|-------------|-------------|-------------|---------|----------------|
| IRF5        | interferon regulatory factor 5 | 2.24 | 0.003 | NM_00108627 |
| IRF7        | interferon regulatory factor 7 | 3.14 | 0.002 | NM_001572 |
| IRF9        | interferon regulatory factor 9 | 2.68 | <0.001 | NM_006084 |
| MYD88       | myeloid differentiation primary response 88 | 1.86 | 0.005 | NM_001172666 |
| HLA-H       | major histocompatibility complex, class I, H (pseudogene) | 2.18 | 0.004 | NR_001434 |
| OAS1        | 2-5-oligoadenylate synthetase 1 | 3.58 | 0.002 | NM_01032409 |
| IFI35       | interferon-induced protein 35 | 1.78 | 0.007 | NM_005533 |
| IFITM3      | interferon induced transmembrane protein 3 | 2.54 | 0.006 | NM_021034 |
| IFNA10      | interferon, alpha 10 | 1.99 | 0.002 | NM_002171 |
| ADAR        | adenosine deaminase, RNA-specific | 3.15 | 0.005 | NM_001025107 |
| OAS3        | 2-5-oligoadenylate synthetase 3 | 4.27 | 0.008 | NM_006187 |
| STAT1       | signal transducer and activator of transcription 1 | 1.75 | 0.008 | NM_007315 |
| KLHL20      | kelch-like family member 20 | −1.94 | 0.004 | NM_014458 |

**Interferon-gamma signaling**

| Gene Symbol | Description | Fold Change | p-Value | mRNA Accession |
|-------------|-------------|-------------|---------|----------------|
| FcGRI1B     | Fc fragment of IgG, high affinity Ib, receptor (CD64) | 2.25 | 0.002 | NM_001004340 |
| PML         | promyelocytic leukemia | 3.18 | 0.002 | NM_002675 |
| STAT1       | signal transducer and activator of transcription 1 | 1.75 | 0.008 | NM_007315 |
| TRIM21      | tripartite motif containing 21 | 2.13 | 0.002 | NM_003141 |
| FcGRI1A     | Fc fragment of IgG, high affinity Ia, receptor (CD64) | 3.2 | <0.001 | NM_000566 |
Table 1. Cont.

| Gene Symbol | Description                                               | Fold Change | p-Value   | mRNA Accession |
|-------------|-----------------------------------------------------------|-------------|-----------|----------------|
| **Inflammatory response** |                                                   |             |           |                |
| CCR4        | chemokine (C-C motif) receptor 4                         | 3.73        | 0.005     | NM_005508     |
| CCR8        | chemokine (C-C motif) receptor 8                         | 2.24        | 0.004     | NM_005201     |
| IL6R        | interleukin 6 receptor                                    | 1.79        | 0.001     | NM_000565     |
| MYD88       | myeloid differentiation primary response 88              | 1.86        | 0.005     | NM_001172566  |
| CSF1        | colony stimulating factor 1 (macrophage)                 | 2.23        | 0.005     | NM_000757     |
| MIF         | macrophage migration inhibitory factor (glycosylation-inhibiting factor) | 2.48        | <0.001    | NM_002415     |
| TNFRSF1A    | tumor necrosis factor receptor superfamily, member 1A    | 4.39        | <0.001    | NM_001065     |
| TGFB1       | transforming growth factor beta 1                        | 1.71        | 0.003     | NM_000660     |
| LTB4R       | leukotriene B4 receptor                                   | 2.46        | <0.001    | NM_001143919  |
| ALOX5       | arachidonate 5-lipoxygenase                              | 2.57        | 0.007     | NM_000698     |
| IL23A       | interleukin 23, alpha subunit p19                        | -2.9        | 0.009     | NM_016584     |
| CXCR3       | chemokine (C-X-C motif) receptor 3                       | 2.25        | 0.002     | NM_001142797  |
| MIF         | macrophage migration inhibitory factor (glycosylation-inhibiting factor) | 2.48        | <0.001    | NM_002415     |
| CEBPD       | CCAAT/enhancer binding protein (C/EBP), delta            | 1.94        | 0.007     | NM_005195     |
| MAP3K12     | mitogen-activated protein kinase kinase kinase 12         | 1.88        | 0.005     | NM_001193511  |
| TRIB2       | tribbles pseudokinase 2                                  | 2.19        | 0.005     | NM_021643     |
| **ECM organization** |                                                   |             |           |                |
| MMP9        | matrix metalloproteinase 9                               | 3.31        | 0.002     | NM_004994     |
| EFEMP2      | EGF containing fibulin-like extracellular matrix protein 2 | 2.43        | 0.001     | NM_016938     |
| ADAM15      | ADAM metallopeptidase domain 15                          | 3.59        | <0.001    | NM_001261464  |
| ADAM8       | ADAM metallopeptidase domain 8                           | 3.13        | <0.001    | NM_001109     |
| BSG         | basigin (Ok blood group)                                 | 2.07        | 0.001     | NM_001728     |
| DAG1        | dystroglycan 1 (dystrophin-associated glycoprotein 1)    | 1.57        | 0.003     | NM_001165928  |
| CTGF        | connective tissue growth factor                          | 1.54        | 0.006     | NM_001901     |
| TGFBI       | transforming growth factor beta 1                        | 1.71        | 0.003     | NM_000660     |
| LOXL3       | lysyl oxidase-like 3                                     | 2.02        | 0.002     | NM_001289164  |
| SPOCK2      | sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 | 2.2         | 0.006     | NM_001134434  |
| **Morphogenesis of a branching epithelium** |                                                   |             |           |                |
| CTSZ        | cathepsin Z                                              | 2.99        | 0.002     | NM_001336     |
| ILK         | integrin linked kinase                                   | 1.82        | 0.001     | NM_001014794  |
| DAG1        | dystroglycan 1 (dystrophin-associated glycoprotein 1)    | 1.57        | 0.003     | NM_001165928  |
### Table 1. Cont.

| Gene Symbol | Description                        | Fold Change | *p*-Value | mRNA Accession      |
|-------------|------------------------------------|-------------|-----------|---------------------|
| EDN1        | endothelin 1                        | -2.17       | 0.002     | NM_001168319        |
| TGFB1       | transforming growth factor beta 1   | 1.71        | 0.003     | NM_000660           |
| GREM1       | gremlin 1                           | 1.53        | 0.009     | ENST00000633992     |
| ENG         | endoglin                            | 2.42        | <0.001    | NM_000118           |

**Epithelial cells polarization**

| Gene Symbol | Description                        | Fold Change | *p*-Value | mRNA Accession      |
|-------------|------------------------------------|-------------|-----------|---------------------|
| ARF6        | ADP-ribosylation factor 6           | 1.53        | 0.008     | NM_001663           |
| FRMD4A      | FERM domain containing 4A           | 1.85        | 0.003     | NM_018027           |
| RHOQ        | ras homolog family member Q         | 1.79        | 0.005     | NM_012249           |
LncRNA profiling showed a statistically significant variation (Bonferroni-corrected $p$-value $\leq 0.01$ and fold change $\geq 1.5$) for 199 long non-coding RNAs (Table S2).

Since modulated genes are well representative of BPs and pathways strictly connected to the disease, we decided to verify whether the modulated lncRNAs could be connected functionally to the pSjS transcriptome, thus playing a role in pSjS pathophysiology.

The identified 199 lncRNAs were then analysed, retaining only those transcripts for which experimentally validated microRNA (miRNA) targets had already been annotated in starBase and, among these, only lncRNAs that targeted at least 10 miRNAs were selected.

Using this approach, we obtained 6 lncRNAs, including CTD-2020K17.1, LINC00657, RP11-169K16.9, LINC00511, RP11-372K14.2 and RP11-214O1.2. (Table 2).

To strengthen the significance of our analysis we wanted to verify the ability of the selected lncRNAs to regulate genes that are differentially expressed in pSjS samples through the interaction with their miRNA targets. We therefore evaluated the entire lists of their miRNA targets that were validated experimentally by high-throughput technologies and selected only those miRNAs that targeted genes modulated in pSjS patients to bona fide outline authentic interactions that are well established in pSjS.

Shown in Table 2, LINC00657, LINC00511 and CTD-2020K17.1 targeted the highest number of modulated genes (Table S3). The expression data were confirmed by RT-PCR (Figure S1).

### Table 2. Selected long non-coding RNAs modulated in pSjS patients versus healthy subjects.

| Gene Symbol | Description | Fold Change | $p$-Value | Public Gene IDs |
|-------------|-------------|-------------|-----------|----------------|
| LINC00657   | long intergenic non-protein coding RNA 657 | 1.8         | 0.001     | NR_027451      |
| LINC00511   | long intergenic non-protein coding RNA 511 | −2.0        | 0.008     | NR_036488      |
| CTD-2020K17.1| novel transcript, antisense to FMNL1 | 2.7         | 0.000     | ENST00000585471.1 |
| RP11-169K16.9| uncharacterized LOC729614 | 1.7         | 0.008     | NR_024279      |
| RP11-214O1.2 | uncharacterized protein MGC12916 | −2.1        | 0.010     | NR_026880      |
| RP11-372K14.2| novel transcript, antisense to SH3D19 | −2.1        | 0.004     | ENST00000603472.1 |

3.3. PPI Network and Modular Analysis of Genes and lncRNAs Modulated in pSjS

Since the modulation of highly connected genes can have a more pronounced effect in the disease pathogenesis than the modulation of genes that are not functionally connected, we evaluated whether the 6 selected lncRNAs could target highly interacting genes in pSjS.

Considering this, to prioritize transcripts that may have a role in the pSjS pathogenesis, we performed a network analysis dissecting all the differentially expressed genes in pSjS that were connected functionally. We therefore constructed a protein–protein interaction (PPI) network that included all the experimentally validated functional interactions among the protein products of the 2503 modulated genes in pSjS (Figure 1A). The obtained network included 2500 modulated genes (nodes) that were connected by 14,169 pairs of interactions (edges) and showed a good PPI enrichment $p$-value ($<10^{-16}$).

Moreover, since genes that are strictly connected to the disease phenotype display a strong tendency to cluster together in few network regions [13], we performed a modular analysis to find
areas in which the most highly connected genes were clustered. Using this approach, we could identify 7 gene modules that are most likely to be involved in the disease pathogenesis (Figure 1B and Table S4). All 7 modules were imported in Cytoscape adding to their scaffolds miRNAs—genes, and lncRNAs—miRNAs interactions.

The topological analysis of such implemented modules highlighted, for the 6 lncRNAs, the lncRNA—gene interactions mediated by their targeted miRNAs. We observed that LINC00657, LINC00511 and CTD-2020K17.1 targeted highly connected genes and the highest number of module-associated genes that were distributed in all the 7 modules (Table 2 and Table S5).

We therefore narrowed our analysis to CTD-2020K17.1, LINC00511, and LINC00657 lncRNAs, since they most probably had a major impact on pSjS transcriptome (as also suggested by the network analysis), (Figure 2).

Noteworthy, targeted genes included several important transcripts involved in T cell development (GATA3), in the response to type I interferon (IRF5, IRF9 and KLHL20), in inflammatory response (IL6R and CEBPD) and in B-cell physiology and malignancy (BAK1, BAX, CBX8, ENO1, GNAI2, HNRNPL, LTBR, TRAF3 and WDR5).

When we analysed the list of miRNAs regulated by the 3 lncRNAs (Table S6), we found that 6 miRNAs played a role in B cell development, for example mir-17-5p, mir-20b-5p, mir-34a-5p, mir-34c-5p, mir-155-5p and mir-93-5p [14,15], and that 51 miRNAs have been previously associated with several types of human B cell lymphomas. Noteworthy, 15 of the above mentioned miRNAs were already associated to pSjS (see Table 3).

Table 3. miRNA targets of the selected lncRNAs that have been associated to lymphoma and/or pSjS.

| IncRNA   | miRNA Target | References                      |
|----------|--------------|---------------------------------|
| LINC00657| hsa-miR-106a-5p | Diffuse large B cell lymphoma [16]             |
| LINC00657| hsa-miR-106b-5p | Diffuse large B cell lymphoma [16]             |
| LINC00657| hsa-miR-144-3p | Diffuse large B cell lymphoma [17]             |
| LINC00657| hsa-miR-155-5p | Diffuse large B cell lymphoma [18]             |
| LINC00511| hsa-miR-15a-5p | Diffuse large B cell lymphoma [19]             |
| LINC00511| hsa-miR-15b-5p | Mantle cell lymphoma [20]                  |
| LINC00511| hsa-miR-16-5p  | Diffuse large B cell lymphoma [21]             |
| LINC00657| hsa-miR-17-5p  | Burkitt’s lymphoma [22]                   |
| LINC00657| hsa-miR-182-5p | Mantle cell lymphoma [22]                   |
| LINC00511| hsa-miR-183-5p | Hodgkin’s lymphoma [23]                   |
| LINC00511| hsa-miR-195-5p | Diffuse large B cell lymphoma [24]             |
| CTD-2020K17.1| hsa-miR-199a-5p | Mantle cell lymphoma [25]                   |
| CTD-2020K17.1| hsa-miR-199b-5p | Diffuse large B cell lymphoma [26]            |
| LINC00657| hsa-miR-20a-5p | Diffuse large B cell lymphoma [16]             |
| LINC00657| hsa-miR-20b-5p | Mantle cell lymphoma [27]                   |
| LINC00657| hsa-miR-22-3p  | Diffuse large B cell lymphoma [28]             |
| LINC00657| hsa-miR-26a-5p | Burkitt’s lymphoma [29]                   |
| LINC00657| hsa-miR-26b-5p | Burkitt’s lymphoma [29]                   |
| LINC00511| hsa-miR-29a-3p | Mantle cell lymphoma [30]                  |
| LINC00511| hsa-miR-29b-3p | Mantle cell lymphoma [30]                  |
| LINC00511| hsa-miR-29c-3p | Mantle cell lymphoma [30]                  |
| LINC00657| hsa-miR-30a-3p | Hodgkin Lymphoma [31]                   |
| LINC00657| hsa-miR-30b-3p | Hodgkin’s Lymphoma [31]; diffuse large B cell lymphoma [32] |
| LINC00657| hsa-miR-302c-3p | Hodgkin’s Lymphoma [31]; mantle cell lymphoma [27] |
| LINC00657| hsa-miR-30a-5p | Non-Hodgkin’s B cell lymphoma [33]             |
| LINC00657| hsa-miR-30b-5p | Non-Hodgkin’s B cell lymphoma [33]             |
| LINC00657| hsa-miR-30c-5p | Non-Hodgkin’s B cell lymphoma [33]             |
| LINC00657| hsa-miR-30d-5p | Non-Hodgkin’s B cell lymphoma [33]             |
| LINC00657| hsa-miR-30e-5p | Non-Hodgkin’s B cell lymphoma [33]             |
| CTD-2020K17.1| hsa-miR-34a-5p | Diffuse large B cell lymphoma [34]             |
Table 3. Cont.

| IncRNA   | miRNA Target     | References                                      |
|----------|------------------|------------------------------------------------|
| LINC00657| hsa-miR-363-3p   | Mantle cell lymphoma [22]                       |
| LINC00657| hsa-miR-372-3p   | Mantle cell lymphoma [27]                       |
| LINC00657| hsa-miR-373-3p   | Mantle cell lymphoma [27]                       |
| LINC00657| hsa-miR-378a-3p  | Hodgkin’s lymphoma [35]                         |
| LINC00657| hsa-miR-378b     | Epstein–Barr virus-associated B-cell lymphoma [36] |
| LINC00657| hsa-miR-378c     | Epstein–Barr virus-associated B-cell lymphoma [36] |
| LINC00657| hsa-miR-378d     | Mantle cell lymphoma [37]; Epstein–Barr virus-associated B-cell lymphoma [36] |
| LINC00657| hsa-miR-378e     | Epstein–Barr virus-associated B-cell lymphoma [36] |
| LINC00657| hsa-miR-378f     | Epstein–Barr virus-associated B-cell lymphoma [36] |
| LINC00657| hsa-miR-378h     | Epstein–Barr virus-associated B-cell lymphoma [36] |
| LINC00657| hsa-miR-378i     | Epstein–Barr virus-associated B-cell lymphoma [36] |
| LINC00657| hsa-miR-421      | Diffuse large B cell lymphoma [32]              |
| LINC00657| hsa-miR-422a     | Burkitt’s lymphoma [38]                         |
| LINC00511| hsa-miR-424-5p   | Diffuse large B cell lymphoma [39]              |
| LINC00511| hsa-miR-497-5p   | Diffuse large B cell lymphoma [24]              |
| LINC00657| hsa-miR-519d-3p  | Diffuse large B cell lymphoma [32]              |
| LINC00657| hsa-miR-520a-3p  | Hodgkin’s Lymphoma [30]                        |
| LINC00657| hsa-miR-520c-3p  | Diffuse large B cell lymphoma [40]              |
| LINC00657| hsa-miR-520d-3p  | Diffuse large B cell lymphoma [41]              |
| LINC00657| hsa-miR-92a-3p   | Diffuse large B cell lymphoma [42]; Non-Hodgkin’s B cell lymphoma [22] |
| LINC00657| hsa-miR-92b-3p   | Mantle cell lymphoma [22]                       |

MiRNAs Previously Associated to pSjS

| IncRNA   | miRNA Target    | References |
|----------|-----------------|------------|
| LINC00657| hsa-miR-106a-5p | [43]       |
| LINC00657| hsa-miR-155-5p  | [44]       |
| LINC00511| hsa-miR-15a-5p  | [43]       |
| LINC00511| hsa-miR-16-5p   | [43]       |
| LINC00657| hsa-miR-17-5p   | [43]       |
| LINC00511| hsa-miR-183-5p  | [45]       |
| LINC00511| hsa-miR-195-5p  | [46]       |
| LINC00657| hsa-miR-20a-5p  | [43]       |
| LINC00657| hsa-miR-20b-5p  | [43]       |
| LINC00657| hsa-miR-26a-5p  | [43]       |
| LINC00657| hsa-miR-30b-5p  | [46]       |
| LINC00657| hsa-miR-30c-5p  | [46]       |
| LINC00657| hsa-miR-32-5p   | [46]       |
| CTD-2020K17.1| hsa-miR-34a-5p | [43]       |
| LINC00657| hsa-miR-378a-3p | [43, 46]   |
3.4. Functional Analysis of Modulated Genes Targeted in the Whole Transcriptome

Once we identified the three lncRNAs that most likely exert a major impact on the whole transcriptome, we wanted to verify if these transcripts could regulate genes that may play a crucial role in the disease.

The three lncRNAs targeted genes involved in several meaningful biological processes. Indeed, LINC00657 regulated a large number of genes involved in cell adhesion including HN1 (F.C. +2.71), ITGA5 (F.C. +2.22), MISP (F.C. +1.86), PRKCE (F.C. −1.62), PTPRJ (F.C. +1.71), RHOC (F.C. +2.5), ZEB1 (F.C. −4.18) and ZFYVE21 (F.C. +3.07) as well as several transcripts that play a role in epithelial cell polarization such as ARF6 (F.C. +1.53), FRMD4A (F.C. +1.859) and RHOQ (F.C. +1.79). Additionally, many genes implicated in apoptosis also were targeted by LINC00657, including ANP32B (F.C. +2.34), BCL2L12 and BCL2L13 (F.C. +2.44 and +2.49 respectively), BMF (F.C. +1.88), BRI3 (F.C. +1.87), CLPTM1L (F.C. +2.8) and ING2 (F.C. +1.97). We also observed that LINC00657 regulated genes involved in T cell development (GATA3, F.C. +1.74) and in T cell activation (ORAI1, F.C. +2.97) as well as genes related to B cell activity, i.e., CBX8 (F.C. +1.62), ENO1 (F.C. +1.91), GNAI2 (F.C. +1.67), SPI1/PU.1 (F.C. +1.73) and TRAF3, a critical regulator of B cell homeostasis (F.C. −1.63). Finally, LINC00657 targeted genes involved in the inflammatory response including CEBPD (F.C. +1.94),
LTB4R (F.C. +2.46), MAP3K12 (F.C. +1.88) and (TRIB2 (F.C. +2.19) and in type I interferon signaling such as IRF5 (F.C. +2.24), IRF9 (F.C. +2.68) and KLHL20 (F.C. –1.94).

Figure 2. Functional interactions among the three selected lncRNAs and genes modulated in pSjS patients. Degree sorted circle layouts of the protein–protein interaction (PPI) network of differentially expressed genes in pSjS patients are shown. Genes (nodes) are ordered around a circle based on their degree of connectivity (number of edges).

LINC00511 regulated a large number of transcripts involved in apoptosis, including BMF (F.C. +1.88), BFAR (F.C. 1.98), DAP (F.C. +2.42) PDCD6 (F.C. +2.93), SORT1 (F.C. +2.51) and RRAGA (F.C. +1.76) whereas CTD-2020K17.1 predominantly targeted differentially expressed genes involved in B cell functions including GNAI2 (F.C. +1.67) HNRNPL (F.C. +2.16) FOSL1/FRA1, the inhibitor of follicular B cell differentiation into plasma cells (F.C. –2.14) and the previously mentioned TRAF3. Moreover, CTD-2020K17.1 also regulated the BAK1 gene (F.C. +2.46) that is frequently overexpressed in B cell lymphomas.

Since it is widely acknowledged that disease phenotypes reflect complex molecular interactions and that human disorders should be considered in terms of perturbations of molecular interaction networks [13], we next performed a pathway enrichment analysis of genes targeted by the three selected lncRNAs.

Signaling pathways involved in apoptosis were enriched in genes targeted by the three lncRNAs which included “Intrinsic Pathway for Apoptosis” (LINC00511, and LINC00657) and “Class I PI3K signaling events mediated by Akt” (CTD-2020K17.1, LINC00511, and LINC00657) (Figure 3 and Table S7).
Figure 3. Meaningful pathways enriched in modulated genes targeted by the three selected lncRNAs. Colored squares indicate pathways enriched in genes targeted by the three lncRNAs: CTD-2020K17.1 (green squares); LINC00657 (red squares); LINC00511 (blue squares). The modules with the same enriched pathways are shown.

Several targeted pathways that play a role in cell-to-cell interactions in epithelial tissue were enriched including: “CDC42 signaling events” (LINC00511 and LINC00657); “E-cadherin signaling events” (LINC00511 and LINC00657); “E-cadherin signaling in the nascent adherens junction” (LINC00511 and LINC00657); “Integrin family cell surface interactions” (LINC00511 and LINC00657); and “Nectin adhesion pathway” (CTD-2020K17.1, LINC00511 and LINC00657).
Signaling pathways involved in cell proliferation also were enriched i.e., “Signaling events mediated by focal adhesion kinase” (CTD-2020K17.1, LINC00511 and LINC00657) and “C-MYB transcription factor network” (LINC00657). Moreover, pathways implicated in branching morphogenesis were targeted including “Canonical Wnt signaling pathway” (LINC00511) and “Proteoglycan syndecan-mediated signaling events” (CTD-2020K17.1, LINC00511 and LINC00657). Interestingly, three pathways regulating salivary gland morphogenesis were targeted by the selected lncRNAs and these encompassed “EGF receptor signaling pathway” (CTD-2020K17.1, LINC00511 and LINC00657), “Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)” (CTD-2020K17.1, LINC00511 and LINC00657) and “BMP receptor signaling” (CTD-2020K17.1). “TGF-beta receptor signaling”, a pathway that influences salivary gland physiology, and its downstream pathway “SMAD signaling” were targeted by LINC00511 and LINC00657.

Several pathways ascribed to the immune response were enriched in modulated targeted genes including “IFN-gamma pathway” (CTD-2020K17.1, LINC00511 and LINC00657), “CD4+ TCR pathway” (CTD-2020K17.1, LINC00511 and LINC00657) and “Role of Calcineurin-dependent NFAT signaling in lymphocytes” (LINC00511). Particularly, several pathways involved in B cell development and activation were enriched including the previously mentioned “Class I PI3K signaling events mediated by Akt” (CTD-2020K17.1, LINC00511, and LINC00657), “CXCR4-mediated signaling events” (LINC00511 and LINC00657), and the mTor signaling (CTD-2020K17.1, LINC00511 and LINC00657).

The three lncRNAs targeted several proinflammatory pathways such as “Interleukin-3” (CTD-2020K17.1, LINC00511 and LINC00657), “Intreleukin-5” (CTD-2020K17.1, LINC00511 and LINC00657) and “Interleukin-8” (LINC00657) signaling, “p38 MAPK signaling pathway” (CTD-2020K17.1), “GMCSF-mediated signaling events” (CTD-2020K17.1, LINC00511 and LINC00657), “Sphingosine 1-phosphate (S1P) pathway” (CTD-2020K17.1, LINC00511 and LINC00657) “TNF alpha/NF-kB” (LINC00657) and the above cited “IFN-gamma pathway” (Figure 3).

3.5. Functional Analysis of Highly Connected Genes that are Included in Modules

Since genes that show the highest number of interactions in the transcriptome most likely are involved in the disease pathogenesis, we next performed a functional analysis of the seven identified gene modules.

Figure 4 summarizes genes targeted in the 7 modules and their respective targeting miRNAs along the most relevant enriched signaling pathways.

M1 included 66 genes and was globally targeted by 29 miRNAs. The top enriched (p ≤ 0.05) pathways in Module M1 were those involved in mRNA processing, including mRNA splicing (Table S8).

M2, included 123 genes and was targeted by 49 miRNAs. Aside from pathways related to cell division (i.e., “DNA Replication”, “Cell Cycle, Mitotic” and “Mitotic M-M/G1 phases”) and energy metabolism (i.e., “Respiratory electron transport”) other meaningful pathways were enriched in this module, including signaling of Interferon alpha/beta and gamma, “Antigen processing-Cross presentation”, “Regulation of Apoptosis”, “Signaling by Wnt” and “TNF alpha/NF-kB” signaling.

M3 included 108 genes and was targeted by 45 miRNAs. “Interferon gamma”, “Interferon alpha/beta”, “Antigen Presentation: Folding, assembly and peptide loading of class I MHC”, “mTOR signaling pathway”, “Class I PI3K signaling events mediated by Akt”, “EGF receptor (ErbB1) signaling pathway” and “GMCSF-mediated signaling events” were among the most relevant enriched pathways in Module M3.

M4 included 101 genes and was the most targeted module, indeed 64 miRNAs were found to be linked to it. This module mostly was enriched in pathways involved in cell metabolism and in other important pathways including “Extrinsic Pathway for Apoptosis”, “IL8-mediated signaling events”, “TNF receptor signaling pathway”, “p38 MAPK signaling pathway” and “CXCR4-mediated signaling events”.

Figure 4. Pathways enrichment of modulated genes included in the modules. Orange circles represent the seven modules and selected enriched pathways in each module are listed in the orange boxes along with their relative statistical significance ($p$-value). Colored pie-charts indicate the percentage of genes targeted in each module by CTD-2020K17.1 (green); LINC00657 (red) and LINC00511 (blue). Colored boxes indicate miRNAs that target genes included in the modules and that are targeted by CTD-2020K17.1 (green box), LINC00657 (red box) and LINC00511 (blue box).
M5 included 74 genes and was targeted by 49 miRNAs. Pathways related to apoptosis were the most enriched in module M5, aside from the “Antigen Presentation” pathway. Other important pathways highly enriched in this module also included “Class I PI3K signaling events mediated by Akt”, “EGF receptor (ErbB1) signaling pathway”, mTOR signaling pathway” and “GMCSF-mediated signaling events”.

M6 included five genes and was targeted by 10 miRNAs. We did not observe any statistical enrichment in Module M6, which was probably due to the small number of genes that composed this cluster.

Finally, M7 included 28 genes and was targeted by 20 miRNAs. “Cytokine Signaling in Immune system”, “TCR signaling in naive CD8+ T cells” and “Immune System” were the most enriched signaling pathways in Module M7. Additional notable pathways enriched in this module were “Signaling by Interleukins”, “GMCSF-mediated signaling events”, “CXCR4-mediated signaling events”, “EGF receptor (ErbB1) signaling pathway”, “Class I PI3K signaling events mediated by Akt”, “Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)”, “IFN-gamma pathway” and “Interferon alpha/beta signaling”.

When we performed a pathway enrichment analysis on the genes targeted within the 7 modules, we found that most of the pathways enriched in the modules also were enriched in the genes targeted in the whole transcriptome. This finding suggests that regulation of highly interactive genes associated with the modules may have a prominent role in the pSjS transcriptome.

4. Discussion

Sjögren’s syndrome is a chronic autoimmune disorder, primarily affecting exocrine glands, and is of unknown origin. The interplay among genetic background, environmental factors, mainly infectious agents, and epigenetics, however, play a pivotal role on the pathogenesis of the disease.

Long non-coding RNAs (lncRNAs) exert a control on gene expression at multiple levels and recently have emerged as crucial components of the epigenetic machinery. Moreover, a growing body of evidence has highlighted the involvement of lncRNAs in different types of autoimmune diseases [47,48].

Several disturbed epigenetic mechanisms, including DNA demethylation, microRNAs modulation and aberrant chromatin positioning have been described in pSjS [49]; however, very little is known of the potential role played by lncRNAs in pSjS. Particularly, a detailed analysis of functional interactions among IncRNA and the pSjS transcriptome has not been attempted yet. During this study we have, therefore, inspected crucial molecular interactions among modulated genes and IncRNAs in pSjS, interactions that may be of relevance in the pathogenesis of the disease.

The expression profiles of a vast number of coding and non-coding genes have been analysed at the same time and, by a multiple step process, modulated lncRNAs that possibly were connected to the pSjS transcriptome were selected.

A sophisticated network analysis was carried out on the entire set of molecular interactions among modulated genes and IncRNAs, thus outlining reliable IncRNA–miRNA–gene functional interactions.

Through a complex network analysis of the whole set of molecular interactions among modulated genes and IncRNAs, we further selected those IncRNAs that targeted modules of the most highly connected genes in the pSjS interactome, since they may have a major impact on pSjS gene modulation. Using this procedure, we chose IncRNAs on the basis of their connectivity (highly versus poorly connected IncRNAs).

Using this approach, we identified three IncRNAs, namely LINC00657, LINC00511 and CTD-2020K17.1, characterized by a high degree of connectivity. Considering this, LINC00657 could exert a prominent role in pSjS gene modulation since it targeted the highest number of highly connected transcripts and, therefore, regulated the vast majority of the disease-related pathways.

Noteworthy, many of the miRNAs targeted by these three IncRNA, which modulate highly connected genes, have been already associated to pSjS.
Several targeted genes with a high degree of connectivity were involved in inflammation, such as the IL-6 receptor (IL6R) and the enhancer of IL-6 production (CEBPΔ) or in the immune response, such GATA3, that is crucial for T cell development, and the three type I interferon-responsive-genes IRF5, IRF9 and KLHL20.

Genes modulated during type I interferon pathway activation (like IRF5 and STAT4) were associated with risk of pSjS, and a type I interferon signature has been described in pSjS patients. Moreover, this signature strongly correlates with the presence of anti-SSA/Ro antibodies [50].

Interestingly, the three lncRNAs also targeted highly connected genes involved in B-cell physiology and malignancy, including IL15 (LINC00657), WDR5 (LINC00657), GNAI2 (LINC00657 and CTD-2020K17.1), LTBR (LINC00511), CBX8 (LINC00657), BAX (LINC00511), ENO1 (LINC00657), HNRNPL (CTD-2020K17.1), and TRAF3 (LINC00657 and CTD-2020K17.1).

The involvement of B cells in the pSjS pathogenesis has been documented well and an increased number of mature B cells have been found in patients with pSjS [51]; interestingly, IL15 and WDR5 play a crucial role in both B cell proliferation and differentiation and GNAI2 regulates B cell trafficking into and within lymph nodes [52]. Moreover, germinal centre (GC)-like structures have been described within the pSjS salivary gland epithelium [51] and, not surprising, LINC00511 and LINC00657 respectively targeted the modulated genes LTBR and CBX8 that are involved on GC formation in inflamed tissues [53,54]. Worth mentioning, three patients presented germinal centre-like structures in their labial salivary gland biopsy.

It has been observed that pSjS patients have an increased risk to develop B cell lymphoproliferative disorders [55] and, noteworthy, BAK1 and BAX are overexpressed in diffuse large B cell lymphoma [56]; ENO1 promotes tumor proliferation in Non-Hodgkin’s Lymphomas and stimulates immunoglobulin production [57]; hnRNPL induces BCL2 overexpression in many B cell lymphomas [58] whereas TRAF3 is a tumor suppressor gene in B lymphocytes and frequently is inactivated in human B lymphoma and multiple myeloma [59]. Interestingly, we found that TRAF3 resulted in down-modulation in our patients with pSjS.

We also observed that several miRNAs targeted by the three lncRNAs that modulated highly connected genes have a documented role in B cell development and in B cell lymphomagenesis. It is worthwhile mentioning that one of the patients developed a B cell lymphoma soon after enrollment in the study.

It has been long recognised that disorders can be viewed in the context of signaling pathway deregulation. We therefore inspected all the signaling pathways that were enriched in modulated genes targeted by the three selected lncRNAs and we discovered that they regulate well-known signaling networks. Moreover, we observed that the vast majority of these pathways also were enriched in all the seven targeted gene modules, thus indicating that the three lncRNAs targeted pathways closely related to the disease pathogenesis.

The selected lncRNAs targeted pathways involved in the development of lacrimal and salivary glands including those of Syndecan (LINC00657, LINC00511 and CTD-2020K17.1), Wnt (LINC00511), TGF-beta receptor (LINC00657 and LINC00511), BMP receptor (CTD-2020K17.1), SMAD proteins (LINC00657 and LINC00511), EGF receptor (LINC00657, LINC00511 and CTD-2020K17.1) and HGF receptor (LINC00657, LINC00511 and CTD-2020K17.1).

The development of both salivary and lacrimal glands is a finely tuned process defined as “branching morphogenesis” that relies on the differential expression of cellular surface receptors and extracellular matrix components like proteoglycans. Indeed, the interactions between cell receptors and ECM elements boost the activation of downstream intracellular signaling pathways that induce the differentiation of progenitor cells into acinar lobules and ducts [60].

Among these pathways, the Wnt signaling is involved in distinct space and temporal patterns during salivary gland development [61] and, interestingly, hypermethylation of this pathway has been observed in salivary gland epithelial cells from patients with Sjögren’s syndrome [62].
TGF-beta also can control salivary gland development by modulating cellular growth and differentiation, moreover, it alters salivary gland physiology by regulating angiogenesis and inflammation [63]. Noteworthy, it has been observed that deletion of TGF-beta signaling in mice salivary glands induces a Sjögren’s syndrome-like autoimmune disorder [63].

The Smad and BMP proteins are downstream mediators of the TGF-beta signaling and influence branching morphogenesis of both lacrimal and salivary glands by promoting mesenchymal proliferation [64,65]. Interestingly, through Smad proteins, TGF-beta also stimulates transcription and subsequent IgA isotype expression in B lymphocytes [66].

Another signaling pathway involved in salivary gland morphogenesis is that of EGF [67], a molecule that also is secreted by lacrimal glands and represents one of the most abundant growth factors in human tears [68]. Particularly, this cytokine can boost migration and proliferation of corneal epithelial cells during wound healing [68].

HGF plays a crucial role in salivary gland development [69] and modulates cell behaviour in acinar and ductal epithelial cells of lacrimal glands [70].

It is well known that the structural and morphological integrity of cell aggregates is pivotal to maintain epithelial functional homeostasis and one of the crucial events involved in the development of autoimmunity is the loss of the mucosal barrier integrity, as in the case of Sjögren’s syndrome, where the protective function of glandular epithelia is compromised [71].

Interestingly, we observed that the three selected lncRNAs target molecular pathways that regulate cell adhesion, for example those of integrins (LINC00657 and LINC00511), E-cadherins (LINC00657 and LINC00511), Nectins (LINC00657, LINC00511 and CTD-2020K17.1), CDC42 (LINC00657 and LINC00511) and focal adhesion kinases (LINC00657, LINC00511 and CTD-2020K17.1).

Marked alteration of integrin expression has been described in pSjS salivary glands [72] and it has been related to the observed detachment of glandular acinar cells. Moreover, elevated serum levels of the soluble form of the adherens junction-associated proteins, E-cadherins, were detected in pSjS patients and it has been related to tissue regeneration induced by chronic inflammation in pSjS glandular epithelia [71]. Additionally, E-cadherins also play a pivotal role in the adhesive interactions between epithelial cells and intraepithelial lymphocytes [73].

To form adherens junctions, E-cadherins associate to the nectin proteins that also are involved in the formation of tight junctions [74]. Specifically, nectins induce activation of Cdc42-mediated signaling, regulating cell polarization and, noteworthy, it has been observed that the secretory dysfunction in pSjS patients also is due to the impairment of epithelial cell polarity [75].

The Cdc42 molecules, in turn, also modulate the activation state of the focal adhesion kinase proteins, another junctional system deregulated in pSjS [71].

Severe disaggregation of the basal lamina associated to the glandular epithelium has been described in pSjS and this event allows inflammatory cells and cytotoxic T lymphocytes to infiltrate acini and ducts [76]. Proteoglycans are a key component of the basal lamina structure and, interestingly, all three lncRNAs targeted proteoglycans, signaling suggesting that they may also be involved in the basal lamina modification, a key feature in pSjS pathogenesis.

Aside from the above mentioned histopathological changes, apoptosis also is involved in pSjS-associated glandular damage, and both apoptotic cells and expression of the apoptosis-regulating proteins have been detected in salivary glands from pSjS patients in many studies [77]. Particularly, it has been suggested that apoptosis might be the initial trigger for autoimmunity in this disease [76] and, noteworthy, proapoptotic signaling pathways also were targeted by the selected lncRNAs.

Leukocyte infiltration in the damaged pSjS glandular epithelium enhances the inflammatory environment that also is sustained by epithelial cell production of adhesion molecules and chemokines [78]. Several proinflammatory pathways were targeted by the selected lncRNAs, including signaling by TNF/NF-Kb (LINC00657), p38 MAP kinase (CTD-2020K17.1), IFN-gamma (LINC00657, LINC00511 and CTD-2020K17.1), GMCSF (LINC00657, LINC00511 and CTD-2020K17.1) and IL-8 (LINC00657).
Tumor Necrosis Factor (TNF) is a strong inducer of NF-kappa B transcription [79] that has been implicated in the development of several autoimmune diseases, and correlates to the chronic inflammation that characterizes pSjS [80]. Moreover, the proinflammatory factor p38 MAP kinase is thought to be involved in the pathogenesis of pSjS [81]. Sphingosine-1-phosphate regulates T cell development and tissue-homing patterns and plays an important role in the local immune responses in pSjS glandular tissue [82]. Moreover, together with IFN-gamma, this molecule is thought to increase IL-6 secretion by pSjS salivary glands [82].

IFN-γ is crucial for T cell differentiation and immunoglobulin class switching in B cells and plays an important role in macrophage activation, inflammation and tissue damage [83]. Moreover, this molecule has been implicated in the development of autoimmunity as well as being associated with more severe forms of pSjS [84].

The immune system has a crucial role in the tissue damage observed in pSjS and both innate and adaptive immunity strongly contribute to this event. Specifically, it has been described that the type-I interferon (IFN-I) signature is involved crucially in the disease pathogenesis [85] and, interestingly, the selected lncRNAs targeted gene modules involved in IFN-I signaling, moreover, they also targeted molecular pathways of the T cell-associated immune response (i.e., TCR and calcineurin-dependent NFAT signaling).

It has been observed that T cells represent the majority of lymphocytes infiltrating the pSjS salivary glands and pro-inflammatory Th1 cell cytokines are increased in saliva of patients with pSjS [86]. Additionally, the presence of regulatory T cells (Treg) also have been identified in pSjS salivary glands and their increased presence is related strongly to a high rate of inflammation in tissue lesions [86]. Noteworthy, the calcineurin-dependent NFAT signaling plays a pivotal role for both development and functions of these cells [87].

There is a body of evidence also supporting the involvement of B cells in pSjS pathogenesis and, indeed, pSjS patients clearly manifest clinical signs of B cell activation [51]. Furthermore, B cells have been identified in the pSjS salivary glands where they can form ectopic germinal centres [51]. As we previously mentioned, we describe that selected lncRNAs can modulate miRNAs involved in B cell development and, interestingly, we also observed that they targeted signaling pathways involved in B cell differentiation and functions such as CXCR4 (LINC00657 and LINC00511) signaling, Class I PI3K and mTor pathways (LINC00657, LINC00511 and CTD-2020K17.1).

Class I PI3K is expressed predominantly by B cells and its signaling pathway is activated promptly upon B cell receptor engagement [88]. Moreover, inhibition of this pathway strongly interferes with pre-B-cell expansion [89]. The PI3k signaling also activates the Akt and mTor pathways which also are involved in B cell proliferation [88] and, noteworthy, their activation has been observed in B cell lymphomas [88]. Finally, an important role for CXCR4 in regulating B cell homeostasis of humoral immunity has been described [90] and noteworthy, a significantly higher expression of both surface CXCR4 and CXCR4 messenger RNA (mRNA) has been reported in peripheral blood B cells from patients with pSjS [91].

We are aware of the limitations of gene expression and microarray analyses, limitations both at preanalytical and analytical levels. Thus, the first, and most important, aspect at a preanalytical level is the correct stratification of the patients and the identification of subjects at the same stage of disease and with similar clinical features. Another important aspect is that the analysis reflects a particular moment in the course of the disease. The method we are reporting here, however, is the most informative for a global evaluation of gene expression, microRNA and lncRNA and, therefore, for the understanding of the genetic and epigenetic processes that play a pivotal role in the pathogenesis of immune-mediated diseases.

5. Conclusions

To conclude, this is the first report that functionally correlates lnc-RNAs modulation to gene expression profiles of pSjS patients. Indeed, the described lncRNAs target gene pathways that are...
involved in important features of the disease, including epithelial cell damage, autoimmunity and B cell hyperactivation. Furthermore, the selected IncRNAs regulate B cell lymphomagenesis-associated microRNAs, thus suggesting their possible involvement in the increased risk to develop lymphoma that is observed in pSS patients.

Taken together, our findings add new pieces of evidence on the importance of epigenetics in the pathogenesis of pSS and may open promising avenues for novel therapeutic approaches to the treatment of the disease.

Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/9/1349/s1, Table S1: Genes modulated in pSS patients versus healthy subjects, Table S2: lncRNAs modulated in pSS patients versus healthy subjects, Table S3: Genes modulated in pSS patients that are targeted by the selected lncRNAs, Table S4: Genes modulated in pSS patients that are included in the 7 Modules, Table S5: Module-associated modulated genes that are targeted by the selected long non-coding RNAs, Table S6: miRNAs targets of the selected lncRNAs that regulated genes included in the seven modules, Table S7: Signaling pathways enriched in modulated genes targeted by the selected IncRNAs, Table S8: Signaling pathways enriched in modulated genes included in modules, Figure S1: Validation by RT-PCR. (A) Expression of the three selected IncRNAs in pSS patients and healthy controls analysed in the study. (B) Expression of selected miRNAs targeted by the three selected lncRNAs in pSS patients and healthy controls analysed in the study. (C) Expression of selected genes modulated in pSS samples and healthy controls analysed in the study. Bars indicate SD; p-values versus healthy controls <0.001.

Author Contributions: Conceptualization, M.D., A.P. and C.L.; Formal analysis, M.D. and E.T.; Investigation, M.D.; Resources, E.T., C.V., N.D.P. and C.L.; Supervision, A.P.; Validation, M.D.; Writing—Original draft, M.D. and A.P.; Writing—Review & editing, A.P. and C.L.

Acknowledgments: We thank the Italian Association of Sjögren’s Syndrome patients (ANIMASS), for donation of some materials used for the experiments.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Maldini, C.; Seror, R.; Fain, O.; Dhote, R.; Amoura, Z.; De Bandt, M.; Delassus, J.L.; Falgarone, G.; Guillevin, L.; Le Guern, V.; et al. Epidemiology of primary Sjögren’s syndrome in a French multiracial/multiethnic area. *Arthritis Care Res.* **2014**, *66*, 454–463. [CrossRef] [PubMed]
2. Mariette, X.; Criswell, L.A. Primary Sjögren’s Syndrome. *N. Engl. J. Med.* **2018**, *378*, 931–939. [CrossRef] [PubMed]
3. Tzioufas, A.G.; Kapsogeorgou, E.K.; Moutsopoulos, H.M. Pathogenesis of Sjögren’s syndrome: What we know and what we should learn. *J. Autoimmun.* **2012**, *39*, 4–8. [CrossRef] [PubMed]
4. Bach, J.F. Infections and autoimmune diseases. *J. Autoimmun.* **2005**, *25*, 74–80. [CrossRef] [PubMed]
5. Shiboski, C.H.; Shiboski, S.C.; Seror, R.; Criswell, L.A.; Labeltoule, M.; Lietman, T.M.; Rasmussen, A.; Scofield, H.; Vitali, C.; Bowman, S.J.; et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. *Ann. Rheum. Dis.* **2017**, *76*, 9–16. [CrossRef] [PubMed]
6. Li, J.H.; Liu, S.; Zhou, H.; Qu, L.H.; Yang, J.H. StarBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-seq data. *Nucleic Acids Res.* **2014**, *42*, D92–D97. [CrossRef] [PubMed]
7. Pathan, M.; Keerthikumar, S.; Ang, C.S.; Gangoda, L.; Quek, C.Y.; Williamson, N.A.; Mouradov, D.; Sieber, O.M.; Simpson, R.J.; Salim, A.; et al. Funrich: An open access standalone functional enrichment and interaction network analysis tool. *Proteomics* **2015**, *15*, 2597–2601. [CrossRef]
8. Jensen, L.J.; Kuhn, M.; Stark, M.; Chaffron, S.; Creevey, C.; Muller, J.; Doerks, T.; Julien, P.; Roth, A.; Simonovic, M.; et al. String 8—A global view on proteins and their functional interactions in 630 organisms. *Nucleic Acids Res.* **2009**, *37*, D412–D416. [CrossRef]
9. Cline, M.S.; Smoot, M.; Cerami, E.; Kuchinsky, A.; Landys, N.; Workman, C.; Christmas, R.; Avila-Campilo, I.; Creech, M.; Gross, B.; et al. Integration of biological networks and gene expression data using cytoscape. *Nat. Protoc.* **2007**, *2*, 2366–2382. [CrossRef]
10. Mi, H.; Muruganujan, A.; Casagrande, J.T.; Thomas, P.D. Large-scale gene function analysis with the Panther classification system. *Nat. Protoc.* **2013**, *8*, 1551–1566. [CrossRef]
11. Fisher, B.A.; Jonsson, R.; Daniels, T.; Bombardieri, M.; Brown, R.M.; Morgan, P.; Bombardieri, S.; Ng, W.F.; Tzioufas, A.G.; Vitali, C.; et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjogren’s syndrome. Ann. Rheum. Dis. 2017, 76, 1161–1168. [CrossRef] [PubMed]

12. Seror, R.; Theander, E.; Brun, J.B.; Ramos-Casals, M.; Valim, V.; Dorner, T.; Bootsma, H.; Tzioufas, A.; Solans-Laqué, R.; Mandl, T.; et al. Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann. Rheum. Dis. 2015, 74, 859–866. [CrossRef] [PubMed]

13. Barabási, A.L.; Gulbahce, N.; Loscalzo, J. Network medicine: A network-based approach to human disease. Nat. Rev. Genet. 2011, 12, 56–68. [CrossRef] [PubMed]

14. Coffre, M.; Koralov, S.B. miRNAs in B Cell Development and Lymphomagenesis. Trends Mol. Med. 2017, 23, 721–736. [CrossRef] [PubMed]

15. Zhang, J.; Jima, D.D.; Jacobs, C.; Fischer, R.; Gottwein, E.; Huang, G.; Lugar, P.L.; Lagoo, A.S.; Rizzieri, D.A.; Friedman, D.; et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009, 113, 4586–4594. [CrossRef]

16. Ni, H.; Tong, R.; Zou, L.; Song, G.; Cho, W.C. MicroRNAs in diffuse large B-cell lymphoma. Oncol. Lett. 2016, 11, 1271–1280. [CrossRef]

17. Wang, H.; Wang, A.; Hu, Z.; Xu, X.; Liu, Z.; Wang, Z. A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion. Cancer Immunol. Res. 2016, 4, 337–344. [CrossRef]

18. Zhu, F.Q.; Zeng, L.; Tang, N.; Tang, Y.P.; Zhou, B.P.; Li, F.F.; Wu, W.G.; Zeng, X.B.; Peng, S.S. MicroRNA-155 Downregulation Promotes Cell Cycle Arrest and Apoptosis in Diffuse Large B-Cell Lymphoma. Oncol. Res. 2016, 24, 415–427. [CrossRef]

19. Hershkovitz-Rokah, O.; Geva, P.; Salmon-Divon, M.; Shpilberg, O.; Liberman-Aronov, S. Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas. Oncotarget 2018, 9, 7928–7941. [CrossRef]

20. Arakawa, F.; Kimura, Y.; Yoshi, N.; Miyoshi, H.; Doi, A.; Yasuda, K.; Nakajima, K.; Kiyasu, J.; Niino, D.; Sugita, Y.; et al. Identification of miR-15b as a transformation-related factor in mantle cell lymphoma. Int. J. Oncol. 2016, 48, 485–492. [CrossRef]

21. Borges, N.M.; do Vale Elias, M.; Fook-Alves, V.L.; Andrade, T.A.; de Conti, M.L.; Macedo, M.P.; Begnami, M.D.; Campos, A.H.; Etto, L.Y.; Bortoluzzo, A.B.; et al. Angiomirs expression profiling in diffuse large B-Cell lymphoma. Oncotarget 2016, 26, 4806–4816. [CrossRef] [PubMed]

22. Di Lisio, L.; Sánchez-Beato, M.; Gómez-López, G.; Rodriguez, M.E.; Montes-Moreno, S.; Mollejo, M.; Menárguez, J.; Martinez, M.A.; Alves, F.J.; Pisano, D.G.; et al. MicroRNA signatures in B-cell lymphomas. Blood Cancer J. 2012, 2, e57. [CrossRef] [PubMed]

23. Xie, L.; Ushmorov, A.; Leithäuser, F.; Guan, H.; Steidl, C.; Färberinger, J.; Pelzer, C.; Vogel, M.J.; Maier, H.J.; Gascoyne, R.D.; et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood 2012, 119, 3503–3511. [CrossRef] [PubMed]

24. Caramuta, S.; Lee, L.; Ozata, D.M.; Akgakaya, P.; Georgii-Hemming, P.; Xie, H.; Amini, R.M.; Lawrie, C.H.; Enblad, G.; Larsson, C.; et al. Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. Blood Cancer J. 2013, 3, e152. [CrossRef] [PubMed]

25. Li, W.; Xue, W.; Wang, X.; Fu, X.; Sun, Z.; Li, Z.; Chang, Y.; Zhang, X.; Zhou, Z.; Chen, C.; et al. MiR-199a mediated the dissemination of human mantle cell lymphoma by interacting with the CCR7/CCL21 pair. Anti-Cancer Drugs 2018, 29, 861–870. [CrossRef] [PubMed]

26. Mazan-Mamczarz, K.; Gartenhaus, R.B. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). Leuk. Res. 2013, 37, 1420–1428. [CrossRef] [PubMed]

27. Di Lisio, L.; Gómez-López, G.; Sánchez-Beato, M.; Gómez-Abad, C.; Rodriguez, M.E.; Villuendas, R.; Ferreira, B.I.; Carro, A.; Rico, D.; Mollejo, M.; et al. Mantle cell lymphoma: Transcriptional regulation by microRNAs. Leukemia 2010, 24, 1335–1342. [CrossRef]

28. Marchesi, F.; Regazzo, G.; Palombi, F.; Terrenato, I.; Sacconi, A.; Spagnuolo, M.; Donzelli, S.; Marino, M.; Ercolani, C.; Di Benedetto, A.; et al. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: An explorative pilot study. J. Exp. Clin. Cancer Res. 2018, 37, 95. [CrossRef] [PubMed]

29. Gao, J.; Liu, Q.G. The role of miR-26 in tumors and normal tissues. Oncol. Lett. 2011, 2, 1019–1023. [CrossRef] [PubMed]

30. Sandhu, S.K.; Croce, C.M.; Garzon, R. Micro-RNA Expression and Function in Lymphomas. Adv. Hematol. 2011, 2011, 347137. [CrossRef] [PubMed]
31. Cordeiro, A.; Monzó, M.; Navarro, A. Non-Coding RNAs in Hodgkin Lymphoma. *Int. J. Mol. Sci.* 2017, 18, 1154. [CrossRef] [PubMed]

32. Lawrie, C.H.; Chi, J.; Taylor, S.; Tramonti, D.; Ballabio, E.; Palazzo, S.; Saunders, N.J.; Pezzella, F.; Boulwood, J.; Wainscoat, J.S.; et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. *J. Cell Mol. Med.* 2009, 13, 1248–1260. [CrossRef] [PubMed]

33. Lin, J.; Lwin, T.; Zhao, J.J.; Tam, W.; Choi, Y.S.; Moscinski, L.C.; Dalton, W.S.; Sotomayor, E.M.; Wright, K.L.; Tao, J. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin’s B-cell lymphomas. *Leukemia* 2011, 25, 145–152. [CrossRef] [PubMed]

34. Marques, S.C.; Ranjarb, B.; Laursen, M.B.; Falgreen, S.; Bilgra, A.E.; Bedker, J.S.; Jørgensen, L.K.; Primo, M.N.; Schmitz, A.; Ettrup, M.S.; et al. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. *Exp. Hematol.* 2016, 44, 238–246. [CrossRef] [PubMed]

35. Yuan, Y.; Kluiver, J.; Koerts, J.; de Jong, D.; Rutgers, B.; Abdul Razak, F.R.; Terpstra, M.; Plaat, B.E.; Nolte, I.M.; Diepstra, A.; et al. miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis. *Am. J. Pathol.* 2017, 187, 1343–1355. [CrossRef] [PubMed]

36. Imig, J.; Motsch, N.; Zhu, J.Y.; Barth, S.; Okoniewski, M.; Reineke, T.; Tinguely, M.; Faggioni, A.; Trivedi, P.; Meister, G.; et al. microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. *Nucleic Acids Res.* 2011, 39, 1880–1893. [CrossRef] [PubMed]

37. Condoluci, A.; Rossi, D.; Zucca, E.; Cavalli, F. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma. *Curr. Oncol. Rep.* 2013, 20, 79. [CrossRef] [PubMed]

38. Lim, E.L.; Marra, M.A. MicroRNA dysregulation in B-cell non-Hodgkin lymphoma. *Blood Lymphat. Cancer Targets Ther.* 2013, 3, 25–40.

39. Khare, D.; Goldschmidt, N.; Bardugo, A.; Gur-Wahnon, D.; Avni, B. Plasma microRNA profiling: Exploring better biomarkers for lymphoma surveillance. *PLoS ONE* 2017, 12, e0187722. [CrossRef]

40. Mazan-Mamczarz, K.; Zhao, X.F.; Dai, B.; Steinhardt, J.J.; Peroutka, R.J.; Berk, K.L.; Landon, A.L.; Sadowska, M.; Zhang, Y.; Lehmann, E.; et al. Down-regulation of elf4GII by miR-520c-3p represses diffuse large B cell lymphoma development. *PLoS Genet.* 2014, 10, e1004105. [CrossRef] [PubMed]

41. Solè, C.; Arnaiz, E.; Lawrie, C.H. MicroRNAs as Biomarkers of B-cell Lymphoma. *Biomark Insights* 2018, 13, 1177271918806840. [CrossRef] [PubMed]

42. Romero, M.; Gaphian, G.; Castro-Vega, L.J.; Acevedo, A.; Wang, L.; Li, Z.W.; El Bouchtaoui, M.; Di Benedetto, M.; Ratajczak, P.; Feugeas, J.P.; et al. Primary mediastinal large B-cell lymphoma: Transcriptional regulation by miR-92a through FOXP1 targeting. *Oncotarget* 2017, 8, 16243–16258. [CrossRef] [PubMed]

43. Reale, M.; D’Angelo, C.; Costantini, E.; Laus, M.; Moretti, A.; Croce, A. MicroRNA in Sjögren’s Syndrome: Their Potential Roles in Pathogenesis and Diagnosis. *J. Immunol. Res.* 2018, 2018, 7910174. [CrossRef] [PubMed]

44. Chen, J.Q.; Zilahi, E.; Papp, G.; Pipka, S.; Zeher, M. Simultaneously increased expression of microRNA-155 and suppressor of cytokine signaling 1 (SOCS1) gene in the peripheral blood mononuclear cells of patients with primary Sjögren’s syndrome. *Int. J. Rheum. Dis.* 2017, 20, 609–613. [CrossRef] [PubMed]

45. Perez, P.; Teos, L.; Tandon, M.; Kazmi, S.; Gallow, A.; Ilii, G.; Alevizos, I. Downregulation of MicroRNA-183 in Sjögren’s Syndrome Minor Salivary Glands; Implications in the Control of ezrin Expression and Salivary Gland Function. In *Proceedings of the 2014 ACR/ARHP Annual Meeting*, Boston, MA, USA, 14–19 November 2014.

46. Wang-Renault, S.F.; Boudaoud, S.; Nocturne, G.; Roche, E.; Sigrist, N.; Daviaud, C.; Bugge Tinggaard, A.; Renault, V.; Deleuze, J.F.; Mariette, X.; et al. Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren’s syndrome. *Ann. Rheum. Dis.* 2018, 77, 133–140. [CrossRef] [PubMed]

47. Wu, G.C.; Pan, H.F.; Leng, R.X.; Wang, D.G.; Li, X.P.; Li, X.M.; Ye, D.Q. Emerging role of long noncoding RNAs in autoimmune diseases. *Autoimmun. Rev.* 2015, 14, 798–805. [CrossRef] [PubMed]

48. Dolcino, M.; Tinazzi, E.; Puccetti, A.; Lunardi, C. In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis. *J. Clin. Med.* 2019, 8, 320. [CrossRef]

49. Konsta, O.D.; Thabet, Y.; Le Dantec, C.; Brooks, W.H.; Tzioufas, A.G.; Pers, J.O.; Renaudineau, Y. The contribution of epigenetics in Sjögren’s Syndrome. *Front. Genet.* 2014, 3, 5–71. [CrossRef]
50. Muskardin, T.L.W.; Niewold, T.B. Type I interferon in rheumatic diseases. Nat. Rev. Rheumatol. 2018, 14, 214–228. [CrossRef]

51. Nocturne, G.; Mariette, X. B cells in the pathogenesis of primary Sjögren syndrome. Nat. Rev. Rheumatol. 2018, 14, 133–145. [CrossRef]

52. Han, S.B.; Moratz, C.; Huang, N.N.; Kelsall, B.; Cho, H.; Shi, C.S.; Schwartz, O.; Kehrl, J.H. Rgs1 and Gna12 regulate the entrance of B lymphocytes into lymph nodes and B cell motility within lymph node follicles. Immunity 2005, 22, 343–354. [CrossRef] [PubMed]

53. Coca, A.; Sanz, I. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjögren’s syndrome. Curr. Opin. Rheumatol. 2018, 30, 197–213. [CrossRef] [PubMed]

54. Béguelin, W.; Teater, M.; Gearhart, M.D.; Calvo Fernández, M.T.; Goldstein, R.L.; Cárdenas, M.G.; Hatzis, K.; Rosen, M.; Shen, H.; Corcoran, C.M.; et al. EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer Cell 2016, 30, 197–213. [CrossRef] [PubMed]

55. Goules, A.V.; Tzioufas, A.G. Lymphomagenesis in Sjögren’s syndrome: Predictive biomarkers towards precision medicine. Autoimmun. Rev. 2019, 18, 137–143. [CrossRef] [PubMed]

56. Bai, M.; Skyrlas, A.; Agnantis, N.J.; Kamina, S.; Tsanou, E.; Grepi, C.; Galani, V.; Kanavaros, P. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax and bak and low expression of the antiapoptotic protein bcl-xl. Mod. Pathol. 2004, 17, 847–856. [PubMed]

57. Zhu, X.; Miao, X.; Wu, Y.; Li, C.; Guo, Y.; Liu, Y.; Chen, Y.; Lu, X.; Wang, Y.; He, S. ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in Non-Hodgkin’s Lymphomas. Exp. Cell Res. 2015, 335, 216–223. [CrossRef] [PubMed]

58. Kishor, A.; Ge, Z.; Hogg, J.R. hnRNP L-dependent protection of normal mRNAs from NMD subverts quality control in B cell lymphoma. EMBO J. 2019, 38, e99128. [CrossRef] [PubMed]

59. Moore, C.R.; Edwards, S.K.; Xie, P. Targeting TRAF3 Downstream Signaling Pathways in B cell Neoplasms. J. Cancer Sci. Ther. 2015, 7, 67–74.

60. Togarrati, P.P.; Dinglasan, N.; Desai, S.; Ryan, W.R.; Muench, M.O. CD29 is highly expressed on epithelial, myoepithelial, and mesenchymal stromal cells of human salivary glands. Oral Dis. 2018, 24, 561–572. [CrossRef]

61. Häärä, O.; Fujimori, S.; Schmidt-Ullrich, R.; Hartmann, C.; Thesleff, I.; Mikkola, M.L. Ectodysplasin and Wnt pathways are required for salivary gland branching morphogenesis. Development 2011, 138, 2681–2691. [CrossRef] [PubMed]

62. Hall, B.E.; Zheng, C.; Swaim, W.D.; Cho, A.; Nageini, C.N.; Eckhaus, M.A.; Flanders, K.C.; Ambudkar, I.S.; Baum, B.J.; Kulkarni, A.B. Conditional overexpression of TGF-beta1 disrupts mouse salivary gland development and function. Lab. Investig. 2010, 90, 543–555. [CrossRef]

63. Mattingly, A.; Finley, J.K.; Knox, S.M. Salivary gland development and disease. Wiley Interdiscip. Rev. Dev. Biol. 2015, 4, 573–590. [CrossRef] [PubMed]

64. Dean, C.; Ito, M.; Makarenkova, H.P.; Faber, S.C.; Lang, R.A. Bmp7 regulates branching morphogenesis of the lacrimal gland by promoting mesenchymal proliferation and condensation. Development 2004, 131, 4155–4165. [CrossRef] [PubMed]

65. Park, S.R.; Lee, E.K.; Kim, B.C.; Kim, P.H. p300 cooperates with Smad3/4 and Runx3 in TGFbeta1-induced IgA isotype expression. Eur. J. Immunol. 2003, 33, 3386–3392. [CrossRef] [PubMed]

66. Harunaga, J.; Hsu, J.C.; Yamada, K.M. Dynamics of salivary gland morphogenesis. J. Dent. Res. 2011, 90, 1070–1077. [CrossRef] [PubMed]

67. Rao, K.; Farley, W.J.; Pflugfelder, S.C. Association between high tear epidermal growth factor levels and corneal subepithelial fibrosis in dry eye conditions. Investag. Ophthalmol. Vis. Sci. 2010, 51, 844–849. [CrossRef]
69. Loreto, C.; Callabiano, R.; Musumeci, G.; Callabiano, C.; Greco, M.G.; Leonardi, R. Hepatocyte growth factor receptor, c-Met, in human embryo salivary glands. An immunohistochemical study. *Anat. Histol. Embryol.* 2010, 39, 173–177. [CrossRef]

70. Li, Q.; Weng, J.; Mohan, R.R.; Bennett, G.L.; Schwall, R.; Wang, Z.F.; Tabor, K.; Kim, J.; Hargrave, S.; Cuevas, K.H.; et al. Hepatocyte growth factor and hepatocyte growth factor receptor in the lacrimal gland, tears, and cornea. *Investig. Ophthalmol. Vis. Sci.* 1996, 37, 727–739.

71. Barrera, M.J.; Bahamondes, V.; Sepulveda, D.; Quest, A.F.; Castro, I.; Cortés, J.; Aguilera, S.; Urzúa, U.; Molina, C.; Pérez, P.; et al. Sjögren’s syndrome and the epithelial target: A comprehensive review. *J. Autoimmun.* 2013, 42, 7–18. [CrossRef]

72. Velozo, J.; Aguilera, S.; Alliende, C.; Ewert, P.; Molina, C.; Pérez, P.; Leyton, L.; Quest, A.; Brito, M.; González, S.; et al. Severe alterations in expression and localisation of [alpha]6[beta]4 integrin in salivary gland acini from patients with Sjögren syndrome. *Ann. Rheum. Dis.* 2009, 68, 991–996. [CrossRef] [PubMed]

73. Jonsson, M.V.; Salomonsson, S.; Øijordsbakken, G.; Skarstein, K. Elevated serum levels of soluble E-cadherin in patients with primary Sjögren’s syndrome. *Scand. J. Immunol.* 2005, 62, 552–559. [CrossRef] [PubMed]

74. Fukuhara, A.; Irie, K.; Yamada, A.; Katata, T.; Honda, T.; Shimizu, K.; Nakanishi, H.; Takai, Y. Role of nectin in organization of tight junctions in epithelial cells. *Genes Cells* 2002, 7, 1059–1072. [CrossRef] [PubMed]

75. Cortés, J.; Hidalgo, J.; Aguilera, S.; Castro, I.; Brito, M.; Urra, H.; Pérez, P.; Barrera, M.J.; Carvajal, P.; Urzúa, U.; et al. Synaptotagmin-1 overexpression under inflammatory conditions affects secretion in salivary glands from Sjögren syndrome patients. *J. Autoimmun.* 2019, 97, 88–99. [CrossRef] [PubMed]

76. Busamia, B.; Gonzalez-Moles, M.A.; Ruiz-Avila, I.; Brunotto, M.; Gil-Montoya, J.A.; Bravo, M.; Gobbi, C.; Finkelberg, A. Cell apoptosis and proliferation in salivary glands of Sjögren’s syndrome. *J. Oral Pathol. Med.* 2011, 40, 721–725. [CrossRef]

77. Manganelli, P.; Fietta, P. Apoptosis and Sjögren syndrome. *Semin. Arthritis Rheum.* 2003, 33, 49–65. [CrossRef] [PubMed]

78. Rodrigues, A.R.; Soares, R. Inflammation in Sjögren’s syndrome: Cause or consequence? *Autoimmunity* 2017, 50, 141–150. [CrossRef] [PubMed]

79. Schütze, S.; Wiegmans, K.; Machleidt, T.; Krönke, M. TNF-induced activation of NF-kappa B. *Immunobiology* 1995, 193, 193–203. [CrossRef]

80. Chen, W.; Lin, J.; Cao, H.; Xu, D.; Xu, B.; Xu, L.; Yue, L.; Sun, C.; Wu, G.; Qian, W. Local and Systemic IKKγ and NF-kB Signaling Associated with Sjögren’s Syndrome Immunopathogenesis. *J. Immunol. Res.* 2015, 2015, 534648. [CrossRef]

81. Sakai, N.; Wada, T.; Furuichi, K.; Yoshimoto, K.; Kitagawa, K.; Kokubo, S.; Kobayashi, M.; Takeda, S.; Kida, H.; et al. p38 MAPK phosphorylation and NF-kappa B activation in human crescentic glomerulonephritis. *Nephrol. Dial. Transplant.* 2002, 17, 998–1004. [CrossRef]

82. Sekiguchi, M.; Iwasaki, T.; Kitano, M.; Kuno, H.; Hashimoto, N.; Kawahito, Y.; Azuma, M.; Hla, T.; Sano, H. Role of sphingosine 1-phosphate in the pathogenesis of Sjögren’s syndrome. *J. Immunol.* 2008, 180, 1921–1928. [CrossRef] [PubMed]

83. Pollard, K.M.; Cauvi, D.M.; Toomey, C.B.; Morris, K.V.; Kono, D.H. Interferon-γ and systemic autoimmunity. *Discoev. Med.* 2016, 123–131. [PubMed]

84. Nezos, A.; Gravani, F.; Tassidou, A.; Kapsogeorgou, E.K.; Voulgarelis, M.; Koutsilieris, M.; Crow, M.K.; Mavragani, C.P. Type I and II interferon signatures in Sjögren’s syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjögren’s related lymphomagenesis. *J. Autoimmun.* 2015, 63, 47–58. [CrossRef] [PubMed]

85. Baldini, C.; Rossi, C.; Ferrero, F.; Santini, E.; Seccia, V.; Donati, V.; Solini, A. The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren’s syndrome. *J. Intern. Med.* 2013, 274, 480–489. [CrossRef] [PubMed]

86. Both, T.; Dalm, V.A.; van Hagen, P.M.; van Dale, P.L. Reviewing primary Sjögren’s syndrome: Beyond the dryness—from pathophysiology to diagnosis and treatment. *Int. J. Med. Sci.* 2017, 14, 191–200. [CrossRef]

87. Oh-hora, M.; Rao, A. The calcium/NFAT pathway: Role in development and function of regulatory T cells. *Microbes Infect.* 2009, 11, 612–619. [CrossRef] [PubMed]

88. Limon, J.J.; Fruman, D.A. Akt and mTOR in B Cell Activation and Differentiation. *Front Immunol.* 2012, 3, 228. [CrossRef]
89. Reth, M.; Nielsen, P. Signaling circuits in early B-cell development. *Adv. Immunol.* **2014**, *122*, 129–175. [CrossRef]

90. Nie, Y.; Waite, J.; Brewer, E.; Sunshine, M.J.; Littman, D.R.; Zou, Y.R. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. *J. Exp. Med.* **2004**, *200*, 1145–1156. [CrossRef]

91. Hansen, A.; Reiter, K.; Ziprian, T.; Jacobi, A.; Hoffmann, A.; Gosemann, M.; Scholze, J.; Lipsky, P.E.; Dörner, T. Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren’s syndrome. *Arthritis Rheum.* **2005**, *52*, 2109–2119. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).